Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Chen

Cardiovascular Disease Corona, CA Doctor of Osteopathy

NPI 1053792366 CMS profile 4639598

341 Magnolia Ave Ste 205, Corona, CA 92879

Open in the dashboard

General payments

$7,870

224 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Chen of Corona, CA is reported in the CMS Open Payments database as having received $7,870 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $448 20
2024 General $730 43
2023 General $421 20
2022 General $1,396 51
2021 General $1,705 42
2020 General $2,375 26
2019 General $795 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Chen
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Brian Chen were reported at $448. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Brian Chen Cardiovascular Disease median Middle half National median
2019 $795 $450 $127–$1,392 $163
2020 $2,375 $242 $77–$751 $114
2021 $1,705 $335 $101–$1,037 $132
2022 $1,396 $395 $121–$1,211 $149
2023 $421 $443 $136–$1,283 $160
2024 $730 $450 $136–$1,323 $164
2025 $448 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,220 24 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $936 34 payments
  3. E.R. Squibb & Sons, L.L.C. $511 18 payments
  4. AstraZeneca Pharmaceuticals LP $453 14 payments
  5. Astellas Pharma US Inc $398 6 payments
  6. Novartis Pharmaceuticals Corporation $372 30 payments
  7. Pfizer Inc. $361 16 payments
  8. Janssen Pharmaceuticals, Inc $337 11 payments
  9. Atricure, Inc. $297 6 payments
  10. Medtronic, Inc. $282 2 payments
  11. Other $1,704 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,709 215 payments
  2. Grant $1,515 2 payments
  3. Education $570 6 payments
  4. Travel and Lodging $76 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $936 34 payments
  2. ELIQUIS $362 14 payments
  3. XARELTO $337 11 payments
  4. ENTRESTO $307 25 payments
  5. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $297 6 payments
  6. FARXIGA $287 9 payments
  7. Resolute $282 2 payments
  8. Repatha $210 12 payments
  9. VYNDAQEL $202 4 payments
  10. Impella $191 5 payments
  11. Other $2,545 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,773

Median for Cardiology: 2,533

Drug cost

$460,606

Median for Cardiology: $485,213

Branded share of claims

31.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 213 $257,188
Xarelto Rivaroxaban Brand 47 $54,080
Farxiga Dapagliflozin Propanediol Brand 42 $46,627
Entresto Sacubitril/Valsartan Brand 25 $34,287
Repatha Sureclick Evolocumab Brand 29 $27,594
Jardiance Empagliflozin Brand 22 $19,891
Metoprolol Succinate Generic 164 $2,770
Rosuvastatin Calcium Generic 162 $2,408
Ranolazine Er Ranolazine Brand 24 $1,711
Losartan Potassium Generic 140 $1,554

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$599,432

Of which drugs: $2,584

Medicare patients

668

Average age 77

Services billed

4,078

375 women, 293 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 48%
Ischemic heart disease 44%
Heart failure 42%
Chronic kidney disease 41%
Atrial fibrillation 33%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 124 453 $2,584

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $155
$155 29 —
XARELTO
  • Janssen Pharmaceuticals, Inc $94
$94 47 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $85
$85 22 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $51
$51 213 —
VYNDAQEL
  • PFIZER INC. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record